Jan 20, 2026 9 min read READ MORE Fitness GLP-1 and Strength Training: Avoiding a Common Pitfall Losing weight on a GLP-1 medication
Antibodies directed against tau protein, including semorinemab, tilavonemab, and gosuranemab, have shown unpromising preliminary results and fail to improve global patient functionality (Walsh et al., 2021

Practical Checklist Before Enrolling in Amble Before starting an intake with Amble or any GLP-1 telehealth platform, a woman should have the following information available: Current weight and height (BMI calculation) List of all medications, including oral contraceptives, metformin, or any insulin Recent labs within the past 12 months, including TSH, HbA1c, and a metabolic panel if available Documentation of any prior weight-loss pharmacotherapy, including which agent, dose, and reason for stopping Clarity on monthly budget including both platform fee and pharmacy cost Understanding that she will need to self-administer a subcutaneous injection weekly and store the pen correctly (refrigerated at 2-8 degrees Celsius) A woman who checks all these boxes, meets BMI criteria, has no contraindications, and can sustain the financial commitment for 12-24 months is a genuinely appropriate candidate for a GLP-1 program through a platform like Amble

Related links CFTR2: Rights and permissions Springer Nature or its licensor (e.g
Several pharmaceutical companies are in the late stages of developing longer-acting formulations that could make this a reality within the next few years